New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH

Ascletis is looking to Takeda veteran Melissa Palmer to move its pipeline of in-licensed and homegrown NASH programs forward.

Ascletis Pharma Inc. (HKEX:1672) announced Monday that Palmer, the former head of liver disease clinical development at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), will join the infectious disease company’s dedicated non-alcoholic steatohepatitis (NASH) unit, Gannex, as its first CMO...